<DOC>
	<DOC>NCT02040792</DOC>
	<brief_summary>This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.</brief_summary>
	<brief_title>A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Subject is a male or female subject 40 years of age or older Subject must have a negative pregnancy test, and must be prepared to use effective contraception if of childbearing potential Subject is capable of performing reproducible spirometry maneuvers Subject has postbronchodilator FEV1/FVC ratio &lt;0.7 Subject has moderatetosevere stable COPD (Stage 2 or 3 according to the GOLD Guidelines) Subject has a postbronchodilator FEV1 greater than or equal to 30% and less than 80% of predicted normal Subject has a current or past smoking history of at least 10 packyears. Subject has a significant respiratory disease or disorder other than COPD that would affect the interpretation of data from this study Subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergic or betaagonist agents Subject suffers from any medical condition that would preclude the use of inhaled anticholinergic agents Subject has been hospitalized for COPD or pneumonia within 12 weeks Subject requires longterm oxygen therapy (&gt;15 hours a day)</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>COPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
</DOC>